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composition	 of	mice	 spleen	 tissue	 under	malarial	 infection,	 compared	with	 non-infected	 samples.	
From	analysis	of	 the	Raman	 imaging	data,	both	 tissue	 types	 showed	very	 similar	 spectral	 profiles,	
which	 highlighted	 that	 their	 biochemical	 compositions	 were	 closely	 linked.	 Principal	 component	
analysis	 showed	 very	 clear	 separation	 of	 the	 two	 sample	 groups,	 with	 an	 associated	 increase	 in	
concentration	of	heme-based	Raman	vibrations	within	the	infected	dataset.	This	was	indicative	of	the	
presence	of	hemozoin,	the	malaria	pigment,	being	detected	within	the	 infected	spleen.	Separation	
also	showed	that	as	 the	hemozoin	content	within	 the	 tissue	 increased,	 there	was	a	corresponding	
change	to	hemoglobin	and	some	lipid/nucleic	acid	vibrations.	These	results	demonstrate	that	Raman	








This	 occurs	within	 the	digestive	 vacuole	of	 the	parasite5	 and	produces	 free	heme	as	 a	by-product	
(ferrous	[FeII]	protoporphyrin	IX)6,	which	is	toxic	to	the	parasite.5		To	detoxify	this,	the	parasite	oxidises	
it	to	an	insoluble,	crystalline	material	known	as	hemozoin	or	the	malaria	pigment.5,7	At	the	end	of	the	





with	 the	elimination	of	parasitised	RBCs	and	hemozoin.9,10	However,	P.	 falciparum	proteins	on	 the	
surface	of	infected	erythrocytes	give	these	cells	the	ability	to	bind	to	endothelial	receptors	in	blood	
vessels	of	tissue,	leading	to	sequestration2,11	of	these	infected	cells	and	hence	reduced	clearance	from	
the	bloodstream.2	 Sequestration	of	parasites	 into	 tissue	 is	 largely	 responsible	 for	 the	 severity	 and	
symptoms	of	 infection12,13,	 therefore,	a	 technique	which	could	non-invasively	detect	 tissue	burden	
would	be	a	great	step	forward.		
Raman	 spectroscopy	 has	 been	 extensively	 used	 for	 the	 identification	 of	 malaria	 infection	 most	
commonly	via	the	detection	of	hemozoin.	It	has	been	widely	reported	by	groups	including	Frosch	et	
al.4	 and	Wood	 et	 al.14	 that	 the	 choice	 of	 Raman	 excitation	wavelength	 is	 key	 to	 gaining	 selective	







reduced	 to	 only	 one	 day,	 following	 Plasmodium	 infection,	 when	 plasma	 samples	 were	 analysed.	
Resonance	Raman	spectroscopy	has	also	been	used	within	a	multimodal	imaging	approach	to	study	
the	disease	mechanisms	of	murine	cerebral	malaria.17	This	work	by	Hackett	et.	al.17	showed	strong	







to	be	gained	without	 the	use	of	 stains.22	During	 the	pathogenesis	of	disease,	biological	alterations	
occur,	which	 lead	to	changes	 in	 the	biochemical	composition	of	affected	tissues.	These	changes	 in	
structure,	concentration	and	composition	of	biomolecules	can	be	reflected	in	the	Raman	spectra	of	
tissue	samples.	Indeed,	Raman	spectroscopy	has	been	used	to	study	the	subtle	molecular	changes	in	
tissue	 samples	 associated	 with	 other	 diseases	 including,	 lung23	 cancer;	 breast20,24	 cancer;	 and	
diabetes.18	
In	 this	 work,	 we	 used	 Raman	 spectroscopic	 imaging	 to	 study	 the	 changes	 in	 the	 biochemical	
composition	of	mouse	spleen	tissue	sections	following	infection	with	the	rodent	parasite,	Plasmodium	
berghei	(P.	berghei).	We	compared	the	Raman	spectra	of	infected	with	non-infected	samples	to	detect	
changes	 in	 the	 Raman	 spectral	 signature	 associated	with	 infection.	 The	multivariate	 chemometric	
analysis	technique,	principal	component	analysis	(PCA)	was	applied	to	decompose	the	spectral	data	






accordance	with	 the	UK	Home	Office	Animals	 (Scientific	Procedures)	Act	1986	 (project	 licence	no.	
P2F28B003).	 Two	 female,	 BALB/c	 mice	 (Harlan,	 Bicester,	 UK;	 6-8	 weeks	 old)	 were	 infected	 with	
asynchronous	P.	berghei	ANKA,	and	euthanised	when	peripheral	blood	parasitemia	reached	5	%.	At	
this	level,	although	high,	the	infection	is	asymptomatic	in	BALB/c	mice.	Spleens	were	removed	from	























Raman	 spectral	 features.	 This	pre-processing	method	applies	 a	 form	of	PCA	 to	 the	dataset,	which	
subsequently	provides	scores	and	loadings	for	each	principle	component	(PC)	to	determine	whether	
components	 primarily	 relate	 to	 real	 Raman	 signals	 or	 noise.	 The	 optimum	 number	 of	 PCs,	 which	
describe	 all	 the	 real	 Raman	 signal	with	minimal	 noise	 interference,	 can	 then	be	 selected	 for	 each	
Raman	map.	Raman	spectra	were	baseline	 corrected	using	an	asymmetric	 least	 square	 smoothing	
algorithm28	 operating	 in	 Matlab	 R2013a	 software	 (The	MathWorks,	 Natick,	 MA,	 USA).	 Finally,	 all	
datasets	were	truncated	so	only	the	fingerprint	region	of	interest	was	studied	(700	–	1700	cm-1).		
The	 reference	 spectra	 shown	are	 the	average	of	 five	 spectra,	 that	were	baselined	using	 the	 same	
asymmetric	least	square	smoothing	algorithm	as	above.		
Empirical	 Analysis.	 In	 this	 study,	 the	 empirical	 analysis	 focused	 on	 the	 ratio	 of	 the	 Raman	 peak	
intensity	at	~745	cm-1	 (v15	hemoglobin)29,30,	 to	 the	peak	 intensity	at	~1307	cm-1	 (v21	hemoglobin	&	
lipids)18,29	for	both	tissue	types.	An	unpaired	student’s	t-test	was	used	to	assess	whether	the	difference	



















approach	 used	 PCA	 to	 determine	 the	 primary	 spectral	 features	 resulting	 in	 correlations	 or	 anti-
correlation	between	 the	 infected	and	non-infected	 tissue,	by	creating	principal	 components	 to	ex-
plain	the	data	set	variance	in	an	unsupervised	manner.	
Figure	 1A	 shows	 the	 averaged,	 normalised	 Raman	 spectra	 obtained	 from	 a	 non-infected	 (control)	
tissue	map	and	a	P	.berghei	infected	mouse	spleen	tissue	map.	Both	tissue	types	showed	a	very	similar	
spectral	profile,	highlighting	that	the	biochemical	compositions	were	closely	 linked.	Tentative	peak	
assignments	of	 the	Raman	bands	are	 listed	 in	Table	1.	However,	differences	 in	 the	relative	Raman	







	Figure	 1.	 Analysis	 of	 Raman	 peak	 intensity	 for	 control	 and	 P.	 berghei-infected	 tissue	 sections.	 (A)	 Averaged,	 normalised	
spectra	from	a	mapped	area	of	control	and	infected	tissue.	Spectra	were	then	normalised	against	the	peak	at	1585	cm-1.	
Tentative	peak	assignments	 are	also	given	 in	 Table	 1.	 (B)	 Subtracted	Raman	 spectrum.	 The	average,	 normalised	 control	





within	 the	area	of	P.	berghei-infected	 tissue	 that	was	mapped	compared	 to	 the	uninfected	area.	These	maps	suggest	an	









intense	 regions	 are	 present	 (Figure	 1C	 and	 S1).	 This	 can	 be	 explained	 through	 enhanced	 Raman	
intensity	 from	 resonance	 contributions	 of	 the	 biological	 components	within	 these	 areas	 of	 tissue.		
These	ratio	maps	visually	show	relative	changes	in	biological	peaks	in	a	sample	manner	and	can	be	
used	 alongside	 empirical	 analysis	 and	 PCA	 to	 aid	 in	 classification	 of	 tissue	 types	 from	 Raman	
spectroscopy	data.		
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mean	 ratios	 for	each	 tissue	 type	were	statistically	 relevant	 (unpaired	student’s	 t-test,	p	<	0.0001).	
Infected	tissue	showed	a	higher	 ratio	value	compared	with	control,	 this	could	be	explained	by	 the	



















hemoglobin.	 The	 negative	 peaks	 at	 ~1529,	 1588	 and	 1628	 cm-1	 match	 closely	 with	 that	 of	 the	
hemozoin	reference	spectra	in	Figure	4	(core	structures	of	hemoglobin	and	hemozoin	shown	in	Figure	
S4	 to	 highlight	 structural	 similarities)	 and	 therefore	 suggest	 detection	 of	 the	 insoluble	 pigment	
through	Raman.	The	negative	~1370	cm-1	peak	 is	present	 in	both	reference	spectra;	however,	 it	 is	
much	more	prominent	within	hemozoin	and	so	suggest	that	hemozoin	is	contributing	to	this	peaks	
appearance	within	 the	 PC1	 loadings	 plot.	 It	 is	 well	 known	 that	 hemozoin	 accumulates	within	 the	
spleen8,9,	therefore	it	follows	that	there	will	be	an	associated	increase	in	concentration	of	heme-based	
Raman	 vibrations.	 This	 is	 clearly	 shown	 in	 this	 PCA	model	 as	many	 of	 these	 peaks	 separating	 the	
infected	tissue	from	the	uninfected	samples	can	be	assigned	to	heme-vibrations,	including	hemozoin.	








































significant	contribution	 from	hemoglobin	 (Figure	4),	however,	 its	broadness	suggests	contributions	


































































































































In	 conclusion,	 a	 combination	 of	 Raman	 imaging	 with	 multivariate	 analysis	 resulted	 in	 very	 clear	








control.	 However,	 due	 to	 the	 resonance	 effects	 of	 heme-based	 compounds	 the	 separation	
contribution	from	these	biological	components	would	have	been	small.		





suitable	 for	 in	 vivo	 diagnostics.	 However,	 with	 the	 development	 of	 spatially	 offset	 Raman	
spectroscopy,	which	allows	accurate	analysis	through	millimetres	of	material	when	obscuring	barriers	
such	as	skin	are	present34,35,	this	may	allow	for	biochemical	information	from	tissue	to	be	detected	in	
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vivo	in	the	near	future.	Overall,	this	approach	demonstrates	the	potential	use	of	Raman	spectroscopy	
to	provide	detailed	chemical	information	from	both	malaria	parasite	infected	and	control	tissue	and	
when	coupled	with	PCA,	discrimination	due	to	infection	burden	is	achievable	between	the	two	sample	
groups.		 	
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